Analyst Reco. Cogent Biosciences, Inc.

Equities

COGT

US19240Q2012

Market Closed - Nasdaq Other stock markets 01:30:00 03/05/2024 am IST			5-day change	1st Jan Change
7.29 ^USD	+5.19%		+21.30%	+23.98%

27/02	North American Morning Briefing : Stock Futures -2-	DJ
26/02	Citigroup Adjusts Price Target on Cogent Biosciences to $13 From $11, Maintains Buy Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Citigroup Adjusts Price Target on Cogent Biosciences to $13 From $11, Maintains Buy Rating	26/02	MT
Baird Downgrades Cogent Biosciences to Neutral From Outperform, Adjusts Price Target to $8 From $14	26/02	MT
Wedbush Raises Cogent Biosciences' PT to $10 From $5, Adjusts Peak Penetration Assumptions for Bezuclastinib in Systemic Mastocytosis; Keeps Neutral Rating	23/02	MT
Citigroup Initiates Cogent Biosciences at Buy Rating With $11 Price Target	08/02	MT
HC Wainwright Adjusts Price Target on Cogent Biosciences to $13 From $27, Keeps Buy Rating	15/12	MT
Wedbush Downgrades Cogent Biosciences to Neutral From Outperform, Cuts Price Target to $5 From $20	11/12	MT
JPMorgan Chase Starts Coverage on Cogent Biosciences with Overweight Rating, $18 Price Target	08/12	MT
HC Wainwright Adjusts Price Target on Cogent Biosciences to $27 From $28, Keeps Buy Rating	08/23/08	MT
Baird Initiates Cogent Biosciences at Outperform With $20 Price Target	28/23/28	MT
Needham Adjusts Price Target on Cogent Biosciences to $23 From $24, Keeps Buy Rating	15/23/15	MT
Wedbush Adjusts Price Target on Cogent Biosciences to $20 From $19, Maintains Outperform Rating	14/23/14	MT
SVB Securities Adjusts Price Target on Cogent Biosciences to $20 From $18, Maintains Outperform Rating	05/23/05	MT
Needham Starts Cogent Biosciences With Buy Rating, Price Target is $24	14/22/14	MT
Guggenheim Adjusts Price Target on Cogent Biosciences to $24 From $22, Maintains Buy Rating	13/22/13	MT
Cogent Biosciences Says Bezuclastinib Shows Overall Response Rate of 73% in Advanced Systemic Mastocytosis Phase 2 Trial	12/22/12	MT
Wedbush Trims Cogent Biosciences' Price Target to $19 From $20, Keeps Outperform Rating	14/22/14	MT
Guggenheim Adjusts Cogent Biosciences Price Target to $22 From $18, Maintains Buy Rating	18/22/18	MT
Wedbush Adjusts Cogent Biosciences Price Target to $20 From $17, Maintains Outperform Rating	09/22/09	MT
SVB Financial Adjusts Cogent Biosciences Price Target to $20 From $15, Maintains Outperform Rating	08/22/08	MT
Guggenheim Starts Cogent Biosciences at Buy With $15 Price Target	28/22/28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Cogent Biosciences, Inc.

Equities

COGT

US19240Q2012

Analyst Reco.

Filters